Laboratory for Health Technology Assessment, Department of Public Health Policy, School of Public Health, University of West Attica, 11521 Athens, Greece.
Ipsen Mepe, 17456 Athens, Greece.
Toxins (Basel). 2023 Sep 8;15(9):561. doi: 10.3390/toxins15090561.
This study aimed to assess the cost-effectiveness of abobotulinumtoxinA (aboBoNT-A) plus Best Supportive Care (BSC) compared with BSC alone for managing limb spasticity in adult patients in Greece, as well as to conduct a budget impact analysis of the introduction of aboBoNT-A in the Greek healthcare system compared to onabotulinumtoxinA (onaBoNT-A). Clinical studies were utilized to extract data on drug efficacy and patients' utility, while cost data were collected from Greek sources. The results of the study showed that aboBoNT-A plus BSC was a cost-effective treatment option for both upper and lower limb spasticity in adult patients compared to BSC. Additionally, introducing aboBoNT-A into the Greek healthcare system resulted in cost savings in pharmaceutical spending over a 5-year period. The findings suggest that incorporating aboBoNT-A into the Greek healthcare system could improve patient access to treatment and healthcare resource efficiency, as it is a more economical option compared to onaBoNT-A.
本研究旨在评估在希腊，与单独最佳支持性治疗（BSC）相比，阿博特菌素 A（aboBoNT-A）联合 BSC 用于治疗成人肢体痉挛的成本效益，并对在希腊医疗保健系统中引入 aboBoNT-A 与奥那博丁 A（onaBoNT-A）进行预算影响分析。临床研究用于提取药物疗效和患者效用的数据，而成本数据则来自希腊来源。研究结果表明，与 BSC 相比，aboBoNT-A 联合 BSC 是治疗成人上肢和下肢痉挛的一种具有成本效益的治疗选择。此外，在希腊医疗保健系统中引入 aboBoNT-A 可在 5 年内节省药物支出。研究结果表明，将 aboBoNT-A 纳入希腊医疗保健系统可以改善患者获得治疗的机会和医疗资源的效率，因为与 onaBoNT-A 相比，它是一种更经济的选择。
